Updated:
Syneos Health
Syneos Health is a publicly traded biopharmaceutical services firm headquartered in Morrisville, integrating clinical development and commercialization.
Syneos Health
Syneos Health was formed in 2017 through the merger of inVentiv Health and INC Research, creating a combined entity that offers end-to-end services for biopharma companies. As a public company, it reports financial results to the SEC and is not structured as a family office or investment vehicle. The firm's strategy focuses on the biopharma lifecycle, with offerings spanning clinical trial management, regulatory consulting, and commercialization services. It serves over 1,200 pharmaceutical, biotech, and medical device clients globally, with operations across North America, Europe, and Asia-Pacific. Key service lines include Phase I-IV clinical trial support, data analytics, and patient recruitment. The firm has not disclosed a proprietary portfolio of investments, as its business model is service-based rather than investment-focused. Syneos Health has over 25,000 employees worldwide, per public filings. It maintains additional offices in multiple countries, including the United Kingdom, Germany, and China. The company is also involved in philanthropic initiatives through a corporate social responsibility framework, though specific foundations are not separately disclosed. In 2023, the firm reported annual revenues of approximately $5.2 billion, as per its 10-K filing. A structural differentiator is its integrated model, which aligns clinical research and commercial deployment under one roof—a less common structure in the CRO industry. However, as a public entity, its operations are transparent and subject to quarterly earnings disclosures rather than the privacy typical of family offices.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Morrisville
Corporate office
Morrisville, NC, United States
Sector focus
Frequently asked questions
Is Syneos Health a family office or investment firm?
No—Syneos Health is a publicly traded biopharmaceutical services company, operating as a contract research organization and commercial partner. It does not manage external capital or function as a family office. The firm provides clinical trial management and commercialization services to pharmaceutical clients.
What is the origin of Syneos Health's wealth and operations?
Syneos Health was created in 2017 via the merger of INC Research and inVentiv Health. Both legacy firms were established CROs: INC Research founded in 2000, inVentiv founded in 1999. The company is publicly held and its value derives from operational revenues rather than a family fortune.
Does Syneos Health invest in external funds or make direct investments?
The firm's core business is service provision, not investment. It does not publicly report a portfolio of fund commitments or direct equity investments. Its capital is deployed in business operations, M&A, and internal R&D, as disclosed in SEC filings.
Which sectors does Syneos Health focus on?
Its operations target the biopharmaceutical industry, particularly therapeutic areas such as oncology, neuroscience, infectious diseases, and rare diseases. It does not actively invest in unrelated sectors like real estate or technology outside of healthcare.
How is Syneos Health structured?
It is structured as a publicly traded corporation with two main segments: Clinical Solutions (CRO) and Commercial Solutions (CCO). It serves clients in over 100 countries and is regulated under SEC reporting requirements.
Does Syneos Health maintain philanthropic foundations?
The firm has a corporate social responsibility program that includes health equity initiatives and community engagement, but it does not operate a distinct, separately endowed family foundation. Specific foundation structures are not publicly detailed.
What recent changes have affected Syneos Health's ownership?
In February 2025, Syneos Health agreed to be acquired by private equity firms for $7.1 billion, taking the company private (per Reuters, February 2025). This transaction ended its listing on the NASDAQ.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: